新鋭醫藥(06108.HK)預計上半年錄得虧損約3650萬港元
格隆匯 8 月 20日丨新鋭醫藥(06108.HK)公佈,預期集團截至2020年6月30日止六個月將錄得虧損約3650萬港元,而2019年上半年則錄得虧損約780萬港元。
集團於2020年上半年的虧損主要由於(i)根據中華人民共和國部分地區新實施的藥品集中採購政策,集團二代頭孢產品(1.0g)下主要產品的平均售價降低導致毛利率減少;(ii)集團的貿易活動及業務經營因2020年爆發Covid-19大流行病而有所放緩;(iii)貿易活動因2020年爆發Covid-19大流行病而有所放緩,導致分攤聯營公司的溢利減少;(iv)於2020年上半年就於集團一間聯營公司Saike International Medical Group Limited的權益確認減值虧損約2220萬港元,而於2019年上半年並無該等減值虧損;及(v)於2020年上半年就集團貿易及其他應收款項確認預期信貸虧損撥備約300萬港元,而於2019年上半年並無該等預期信貸虧損撥備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.